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Abstract
Background. Radical re-resection is offered to patients with non-metastatic, invasive, incidental gallbladder cancer. Data
evaluating 18F-fluorodeoxyglucose positron emission tomographycomputed tomography (18F-FDG PETCT) in patients
with incidental gallbladder cancer is sparse. Aim. To evaluate the efficacy of integrated 18F-FDG PETCT in determining
occult metastatic or residual localregional disease in patients with incidental gallbladder cancer. Methods. Patients referred
with incidental gallbladder cancer for radical re-resection were evaluated using multidetector computed tomography
(MDCT) and PETCT. Based on preoperative imaging, 24 out of 92 patients were found suitable for surgery. The two
imaging modalities were evaluated with respect to residual and resectable disease. Results. In determining residual disease,
MDCT had a sensitivity and positive predictive value (PPV) of 42.8%, each, while PETCT had a sensitivity and PPV of
28.5 and 20%, respectively. In determining resectability, MDCT had a sensitivity, PPV, and accuracy of 100, 87.5, and
87.5%, respectively, as compared to PETCT (sensitivity100%, PPV91.3%, accuracy91.6%). Conclusions. From our
study, it appears that in patients with incidental gall bladder cancer without metastatic disease, PETCT and MDCT seem
to have roles complementing each other. PETCT was able to detect occult metastatic or residual localregional disease in
some of these patients, and seems to be useful in the preoperative diagnostic algorithm of patients whose MDCT is normal
or indicates locally advanced disease.
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Introduction
Radical re-resection remains the most effective tool in
the management of patients with incidental gallblad-
der cancer [1,2]. It is indicated in all patients with
lesions T1b and T2 (determined on the histopatho-
logical examination of the excised specimen of the
simple cholecystectomy) [39], in the absence of
metastatic disease. Surgery does not offer any survival
benefit in gallbladder cancer in patients with distant
metastasis. Further, incomplete resection is associated
with an equally dismal prognosis [10,11]. It is there-
fore, important to detect patients who have advanced
disease and are unlikely to benefit from an exploratory
surgery [12]. This would facilitate offering these
patients palliative treatment options or enrolling
them into research protocols.
The currently used imaging modalities for preopera-
tive staging of the disease include multidetector com-
puted tomography (MDCT) scanning and magnetic
resonance imaging (MRI)/magnetic resonance cholan-
giopancreatography (MRCP). MDCT is a useful tool
in staging of the disease by identifying the presence of
residual disease in the gallbladder fossa and also
regional metastasis to the lymph nodes draining the
gall bladder, liver, and ascites. However, there does
exist the possibility of understaging the disease since
these imaging modalities may not detect distant spread
as well as peritoneal and/or omental deposits.
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PET is a functional imaging modality that avails the
high utilization of glucose in tumor cells. This is
utilized in imaging for cancer where the higher rates of
phosphorylation and the low rates of dephosphoryla-
tion result in the accumulation of FDG-6-phosphate
(generated by the introduction of 18F-FDG into
tumor cells). The poor anatomic localization of the
positive PET lesions is overcome by combining the
PET images with contrast-enhanced CT images
(PETCT).
Data evaluating 18F-fluorodeoxyglucose positron
emission tomographycomputed tomography (18F-
FDG PETCT) in patients with incidental gallblad-
der cancer is sparse. However, there is no study
comparing, or exploring the complementary role on
the use of PETCT and MDCT in the preoperative
evaluation of patients with incidental gallbladder
cancer who are being considered for radical re-
resection.
We designed this study with intent to evaluate the
efficacy of integrated 18F-FDG PETCT in deter-
mining the presence of occult metastatic or residual
localregional disease after the gallbladder has been
removed and also to determine the benefit of adding a
PETCT to the already existing information from
MDCT in determining resectability. We hoped to
determine the role of PETCT in the diagnostic
algorithm prior to radical re-resection for incidental
gallbladder cancer.
Materials and methods
Patients referred to the Department of Gastrointest-
inal Surgery, Tata Memorial Hospital between
1st December 2006 and 31st October 2007, with
incidental gallbladder cancer and planned for radical
re-resection (based on the histopathological review of
the resected specimen indicating the tumor to be
]pT1b) were evaluated using MDCT (see Figure 1).
In patients with no evidence of metastasis on MDCT
and with no evidence of disease in the gallbladder
fossa or with locally advanced disease, a PETCT was
performed to rule out distant metastasis. Of a total of
92 patients, 56 patients had advanced metastatic
disease based on MDCT and PETCT imaging and
were thus advised palliative chemotherapy while
12 patients were excluded from the study for logistical
reasons. Thus 24 patients in whom the MDCT and
PETCT scan findings were suggestive of localized
disease or no disease were included in the study.
These patients underwent radical re-resection which
included the clearance of the following nodes: cystic,
pericholedochal, hepatic hilar, hepatic, retroportal,
posterior pancreatoduodenal, and celiac. In addition,
a non-anatomical 3 cm-wedge resection of the gall
bladder bed (segments IV B and V) was performed. In
all patients, the cystic duct stump was identified and
revised (with negative margins confirmed by frozen
section). In case of a positive revised margin (on
frozen section) of the cystic duct that was flush with
the common bile duct, the patient was subjected to a
radical extrahepatic bile duct excision with a hepati-
codochojejunostomy.
Preoperatively, all patients were investigated with
routine blood investigations, including blood counts,
liver and renal functions, and serum tumor marker
CA 19-9.
MDCT
Preoperative evaluation included a contrast-enhanced
CT study of the abdomen and pelvis on a 16-slice
MDCT scanner. Sections were acquired from the
domes of diaphragm to the ischial tuberosities.
Hundred milliliters of nonionic iodinated contrast
was injected @ 3 ml/second and images acquired after
a 65-second delay. Images were acquired with 5 mm
collimation and reconstructed at 1.25 mm. Coronal
and Sagittal reformats were also studied along with
bone and soft tissue settings. CT parameters used
were 120 kvp, 200 mA, pitch of 1.375 and FOV was
35 cm. The criteria used for unresectability were:
distant metastasis (liver or peritoneal lesions), exten-
sive contiguous organ invasion (liver, duodenum),
invasion of biliary confluence, invasion of main portal
vein, or proper hepatic artery. Lymph nodes were
considered positive if they were greater than 10 mm in
maximum axial diameter or if there were features of
necrosis (heterogeneous contrast enhancement).
A prepared proforma was used to evaluate every
MDCT so as to accurately and uniformly interpret
the scan.
PETCT
The PETCT scan was performed at a median
duration of 51 days (range 17152) after the first
surgery.
Patient preparation and PETCT imaging protocol. All
patients were asked to fast for 46 hours prior to the
study and blood glucose levels were checked and
confirmed to be less than 150 mg/dl. The studies were
performed one hour following intravenous adminis-
tration of 370 MBq (10 mCi) of 18F-FDG during
which period patients were asked to rest. Patients were
asked to drink 750 ml of water soluble iodinated oral
contrast to opacify the bowel for the CT component
of the study. No intravenous iodinated contrast was
administered. Patients were positioned supine with
their arms to their sides and were asked to breathe
normally during image acquisition.
Imaging was performed on a Discovery ST PET
CT system (GE medical systems).
It combines a 16 slice CT scanner with a dedicated
PET (BGO plus crystal, dimensions 3.8 mm
3.8 mm3.8 cm).
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A CT was performed over 57 bed positions from
the skull base to the mid-thigh level using multislice
(16 slice) CT component of the system. CT para-
meters included 140 kV, 110 mA, 0.8 s/rotation, pitch
of 1.75:1, FOV 50 cm, length of scan 1.01.6 m,
0.625 spatial resolution and slice thickness of 3.75
mm.
This was followed immediately by acquisition of
PET data in the same anatomic locations with 15.4
cm axial FOV acquired in 2D mode with 23 min/bed
position.
The total acquisition time accumulating between
100 and 150 million useful events varied between 15
and 20 minutes.
Image reconstruction and interpretation. CT data ob-
tained was used for attenuation correction of PET
images, and images were reconstructed using a
standard vendor provided reconstruction algorithm
which incorporated ordered subset expectation max-
imization (OSEM). Image fusion was performed
Incidental gallbladder cancer
(CAGB) confirmed on histopathology 
MDCT scan of abdomen and pelvis 
Non-metastatic disease Metastatic disease
PET-CT whole body 
ctive disease present
(and MDCT s/o locally
advanced disease)   
No active
disease
Radical re-resection 3 cycles
chemotherapy
and then
reassess  
Disease
regression /
static 
Yes 
No 
Progressive
disease 
Resectable disease 
Yes No 
Palliative therapy
(chemotherapy, best
supportive care, ERCP
/PTBD and stenting
Figure 1. Algorithm for evaluation and management of incidental gallbladder cancers.
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using co-ordinate-based fusion software and subse-
quently reviewed at a workstation (Xeleris) that
provided multiplanar reformatted images and dis-
played PET images, CT images and PETCT fusion
images.
Studies were interpreted independently by a Nu-
clear Medicine specialist and a Radiologist. The CT
data was used for anatomical localization and corro-
boration of the PET findings.
Before surgery, the MDCT images were interpreted
by a radiologist who was blinded to the results of the
PETCT scan.
The algorithm used for management has been
shown in Figure 1.
Perioperative mortality was defined as death during
the hospitalization following surgery or within 30 days
of surgery.
The total hospital course was defined from the date
of surgery until the patient was discharged.
All statistical analyses were performed using SPSS
Version 14.0 for Windows. The continuous data were
expressed as mean9standard deviation. The sensitiv-
ity (number of true positives, i.e. patients with occult
metastatic or residual localregional disease correctly
detected by the test), specificity (number of true
negatives, i.e. patients who do not have occult meta-
static or residual localregional disease and correctly
detected by the test), and the positive (patients in
whom the test is positive and actually have occult
metastatic or residual localregional disease) and
negative (patients in whom the test is negative and in
whom there is actually no occult metastatic or residual
localregional disease) predictive values (positive pre-
dictive value, PPV and NPV) and accuracy were
calculated individually for PETCTand MDCT using
histopathology as the gold standard.
Results
Patient demography and tumor characteristics
Of the 24 patients, there were eight male and 16
female patients. The mean age was 45.3911.4 years.
In 12 patients, the first surgery (simple cholecystect-
omy) had been performed laparoscopically, while 12
patients underwent prior open cholecystectomy.
Review of the histopathology of the first surgery
indicated the histology as adenocarcinoma (well
differentiated 2, moderately differentiated 16,
and poorly differentiated 6). By pT-stage, seven
patients had T1b disease while, 12 and five patients
had T2 and T3 disease, respectively.
The median CA19-9 level was 6.8 U/ml (range 0
2021).
Resectability
Although 24 patients were explored with an intent to
perform a radical re-resection based on the preopera-
tive imaging suggestive of localized or no active
disease, three patients were found to have metastatic
disease (peritoneal/omental) or locally advanced dis-
ease (fixed portal mass). Thus, the intended proce-
dure could be completed in 21 patients (87.5%)
Although preoperative MDCT had predicted resect-
ability in 24 patients, three patients had unresectable
disease. MDCT had indicated the presence of a mass
in the gallbladder fossa in two of the three patients.
However, it neither predicted the presence of dissemi-
nated disease, nor were there findings suggestive of
unresectability in these three patients (sensitivity
100%, PPV87.5%, accuracy87.5%). PETCT
predicted resectability in 23 patients (sensitivity
100%, PPV91.3%, accuracy91.6%). In the three
patients who were unresectable, PETCT had indi-
cated the presence of regional disease in one of the
three patients.
There was no statistical difference between MDCT
and PETCT in predicting resectability once distant
disease was excluded.
Residual disease
On the histopathological examination of the excised
scar, gallbladder wedge, dissected lymph nodal tissue
(hepatic, portal, pericholedochal, retroduodenal,
paraaortic/interaortocaval), residual disease was
found in seven patients.
Of the seven patients with histopathologically
proven residual disease, MDCT had predicted the
likelihood of residual disease in three patients
(sensitivity42.8%, PPV42.8%) while PETCT
had predicted the likelihood of residual disease in two
patients (sensitivity28.5%, PPV20%).
Tables I and II show a complete site-wise break-up
of the specificity, NPV and accuracy of MDCT and
PETCT in detecting residual disease in patients with
incidental gallbladder cancer. Figure 2 summarises
the final outcomes of all the 92 patients with
incidental gallbladder cancer.
Table I. Analysis of MDCT based on the detection of residual
disease in the various regions on the final histopathological
assessment (n24).
Specificity NPV Accuracy
Scar 95 82.6 79.1
GB fossa 89.4 94.4 80.9
Liver metastasis 100 100 100
Hepatic node 90 94.7 85.7
Portal node 100 90.4 90.4
Retroduodenal node 95.2 100 95.2
Pericholedochal node 100 90.4 90.4
Paraaortic node 90.4 100 90.4
Regional disease 100 91.3 91.6
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Discussion
Owing to the biological aggressiveness of the disease,
there appears to be no long-term survival in patients
with gallbladder cancers with distant metastasis 
macroscopic or occult. The detection of distant
disease helps in avoiding an unnecessary exploration.
At present, the most commonly employed and
effective method for the preoperative staging of
gallbladder cancer is MDCT which allows fast scan-
ning with thin sections and high resolution volumetric
reconstructions. This permits a more accurate detec-
tion of liver infiltration by the tumor in the gallbladder
infiltration while minimizing partial volume artifacts,
thereby improving T staging of the tumor [1315].
However, as yet there are no studies evaluating the
role of MDCT in detecting residual disease or
determining resectability (for radical re-resection) in
patients with incidental gallbladder cancer.
While it does constitute an important investigation
in the preoperative setting, the inability to pick up
peritoneal seedlings and small hepatic metastasis
coupled with the fact that there remains the possibility
of missing regional lymphadenopathy, there exists a
chance of understaging of the disease as pointed out
by Donohue et al. [16].
The use of 18F-FDG in the diagnostic work-up of
oncological patients is well established [17,18]. Stu-
92 patients with incidental
gallbladder cancer  
MDCT and / or PET-CT 
Non-metastatic disease
(n=24) – explored with
curative intent  
Metastatic disease
(n=56) 
MDCT – hepatic 
metastasis (confirmed on 
guided FNAC) 
or 
Normal MDCT Abdomen 
and pelvis      PET-CT 
done revealed  
1) foci of distant 
metastasis, viz. 
supraclavicular, 
mediatinal, axillary lymph 
nodes 
2) lung mets 
(Confirmed on guided 
FNAC or biopsy) 
12 patients excluded from study 
Palliative therapy
(chemotherapy, best
supportive care, ERCP
/PTBD and stenting
Radical re-resection
(n=21)  
3 patients
inoperable  
Correctly predicted
MDCT - 0
PET-CT - 1 
Correctly predicted
MDCT – 3 (out of 7)
PET-CT–2(out of 7)   
Residual disease in 7 patients 
Figure 2. Flow chart of the 92 patients with incidental gallbladder cancer who were considered candidates for potentially curative surgery
and their final outcomes.
Table II. Analysis of PETCT based on the detection of residual
disease in the various regions on the final histopathological
assessment (n24).
Specificity NPV Accuracy
Scar 80 80 66.6
GB fossa 89.4 94.4 85.7
Liver metastasis 100 100 100
Hepatic node 100 95.2 95.2
Portal node 100 90.4 90.4
Retroduodenal node 95.2 100 95.2
Pericholedochal node 100 90.4 90.4
Paraaortic node 100 100 100
Regional disease 80.9 85 70.8
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dies exploring the benefit of PET specifically for
gallbladder cancer are few [1924]. These studies,
which have essentially focused on the use of PET
imaging for the preoperative evaluation of primary
gallbladder cancers, have reported sensitivities of 75
100%. Till date there is only one study comparing
PETCT versus contrast-enhanced CT in primary/
occult metastatic or residual localregional gallblad-
der cancers [25].
Determination of resectability
MDCT remains a useful investigation for detecting
gross metastatic disease in the abdomen and pelvis in
patients with incidental gallbladder cancer who are
being considered for radical re-resection. The addi-
tion of PETCT to the diagnostic algorithm further
helps in narrowing down those patients with meta-
static disease outside the fields of study of the MDCT.
In our study there was only one patient in whom the
PETCT had indicated the likelihood of unresect-
ability by virtue of increased regional FDG uptake.
Based on the MDCT we, however, did explore this
patient only to find the disease not amenable to a
resection. While this is only a single case, it does
highlight that there may be a need to further clarify
the features on PETCT that may indicate the like-
lihood of unresectability. This may further improve
the clinical application of PETCT in patients with
incidental gallbladder cancer.
On comparing our resectability rates between two
time periods, i.e. from January 2003 to November
2006 and the current series, our resectability rates
appear to have improved. Out of 72 patients explored,
resectable disease was found in 53 patients (73.6%) as
opposed to 21 out of 24 patients in the current series
(87.5%). It is important to note that the (R0)
resectability rate in the entire group is 87.5% which
is indicative of the benefit of combining the two
investigative modalities.
The false negative results of PETCT in our series
corroborate with the findings of Anderson et al. [23]
who studied the role of PET in 14 patients with
gallbladder cancer. They felt that these results were
due to the small size of the lesions which escaped
detection by the equipment. In fact, low sensitivity for
peritoneal disease has also been reported for PET in
the case of gastric cancer [26]. This low sensitivity is
also seen with MDCT.
Determination of residual disease
As seen in Tables I and II, the specificity, accuracy,
and NPV are high. This indicates the ability of the two
diagnostic imaging modalities to correctly diagnose
the absence of disease. The low sensitivity of PET in
detecting microscopic disease has been reported ear-
lier in relation to ovarian cancer [27]. There were
seven patients with false positive FDG uptake in the
scar. The PETCT in these four patients was
performed at mean interval of 53923.1 days after
the first surgery. This may be argued in favor of FDG
avidity to the inflammatory process within the scar
[28]. In fact the only previous report of a false positive
FDG uptake in post-surgical gallbladder cancer
patients was noted by Anderson et al. [23] who felt
that this may occur if the PETCT is performed
within one month of the first surgery.
Our study proves that PETCT is capable of
detecting occult metastatic or residual localregional
gallbladder cancer and thus provides the basis for
further exploring the role of PETCT in patients with
incidental gallbladder cancer.
Our study is unable to provide sufficient evidence to
state that PETCT improves resectability rates. How-
ever, it does provide the impetus for further exploring
whether there exist PETCT criteria that can clearly
determine resectability. With further improvements in
the ability of PETCT imaging to detect smaller
lesions, the role of nuclear imaging in preoperative
staging of malignant disease will only increase.
In conclusion, it appears that the prime advantage
of PETCT over MDCT is its ability to detect occult
metastatic disease in the rest of the body as opposed
to MDCT of the abdomen and pelvis which is useful
in the loco-regional staging of the disease. This study
thus provides an important indication for the use of
PETCT, that is, in patients with incidental gallblad-
der cancer since the detection of clinically occult
metastasis using PETCT scan will help identify those
patients who will not benefit from a radical resection
and who would be better served by palliative care
strategies.
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